The World Health Organization (WHO) has published a report titled “Catalysing solutions for equitable global access and sustainable financing for novel tuberculosis vaccines for adults and adolescents.” The document was prepared by the Working Group on Financing and Access of the TB Vaccine Accelerator Council.
On October 29, 2025, the Board of the Eurasian Economic Commission (EEC) approved for signature a new three-year action plan to implement the 2021 Memorandum of Understanding with the World Health Organization’s Regional Office for Europe.
The biopharmaceutical company Bluejay Therapeutics is conducting clinical trials of a novel therapeutic candidate, Brelovitug (BJT-778), developed for the treatment of chronic hepatitis delta (hepatitis D). In 2025, two global Phase III clinical studies — AZURE-1 and AZURE-2 — were launched to evaluate the efficacy and safety of the drug.
On October 14, Brussels hosted a panel discussion titled “Removing Barriers: Ensuring Access to Essential Tuberculosis Medicines in the EU and EEA,” organized by Médecins Sans Frontières (MSF). The event brought together representatives of European institutions, the World Health Organization (WHO), national health authorities, and civil society organizations.
